Overexpression of PSAT1 Gene is a Favorable Prognostic Marker in Lower-Grade Gliomas and Predicts a Favorable Outcome in Patients with IDH1 Mutations and Chromosome 1p19q Codeletion

• Published in: Cancers Vol. 12; no. 1; p. 13
• Main Authors: Huang, Shang-Pen, Chan, Yung-Chieh, Huang, Shang-Yu, Lin, Yuan-Feng
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 18.12.2019; MDPI
• Subjects: Bioinformatics; Biomarkers; Brain cancer; Breast cancer; Carbon; Cell cycle; Cell growth; Chromosome 1; Chromosomes; Colorectal cancer; Dehydrogenases; Enzymes; Gene expression; Genomes; Glioma; Isocitrate dehydrogenase; Liver cancer; Lung cancer; Medical prognosis; Metabolism; Metabolites; Mutation; p53 Protein; Phosphoglycerate dehydrogenase; Phosphoserine; Phosphoserine aminotransferase; Phosphoserine phosphatase; Serine; Survival; Tumors; CGGA; IDH1 mutation; PSAT1; 1p19q codeletion; lower-grade gliomas (LGGs); biomarker; prognosis; TCGA
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers12010013

Patients with lower-grade gliomas (LGGs) have highly diverse clinical outcomes. Although histological features and molecular markers have been used to predict prognosis, the identification of new biomarkers for the accurate prediction of patient outcomes is still needed. The serine synthesis pathway (SSP) is important in cancer metabolism. There are three key regulators, including phosphoglycerate dehydrogenase (PHGDH), phosphoserine phosphatase (PSPH), and phosphoserine aminotransferase 1 (PSAT1), in SSP However, their clinical importance in LGGs is still unknown. In this study, we used the bioinformatics tool in the Gene Expression Profiling Interactive Analysis (GEPIA) website to examine the prognostic significance of , , and genes in LGGs. gene expression was then identified as a potential biomarker candidate for LGGs. Datasets from The Cancer Genome Atlas (TCGA) and the Chinese Glioma Genome Atlas (CGGA) were further used to explore the prognostic role of gene. Our results demonstrated that overexpression is a favorable prognostic marker of LGGs and significantly correlated with patient age ≤40, and a lower WHO histological grade, as well as mutations in IDH1, TP53 and ATRX, but not with chromosome 1p19q codeletions. More importantly, LGG patients with isocitrate dehydrogenase 1 (IDH1) mutations, chromosome 1p19q codeletions, and overexpression may have the best overall survival (five-year survival rate: 100%). Finally, we observed a coordinated biological reaction between IDH1 mutations and overexpression, and suggested overexpression of might enhance the function of mutant IDH1 to promote a favorable outcome in LGG patients. In conclusion, our study confirmed the importance of identifying the overexpression of as a favorable prognostic marker of LGGs, which may compensate for the limitation of mutations and chromosome 1p19q codeletion in the prognostication of LGGs.